Abstract
Objectives: A new national clinical guideline for the management of tuberculosis and HIV in Iranian prisons was released in 2011. The aim of this study was to compare HIV indicators in the case and control prisons after implementation of the new guideline.
Methods: This report examines outcomes observed during the pilot phase of its implementation at a case prison from October 2013 to June 2014 compared to a control prison that had not yet implemented the guideline. The case prison included incarcerated individuals in the Great Tehran Prison. A prison in Alborz province was considered as a control group. Pearson’s Chi-squared, two-sample t-test, paired t-test and Kruskal-Wallis were used for the analysis.
Results: The intervention significantly increased the total number of inmates tested for HIV and of diagnoses of HIV-positive inmates in the case prison compared to the control prison (P<0.001). Moreover, coverage of antiretroviral therapy was higher in the case prison compared to the control prison (P=0.015).
Conclusion: We recommend the implementation of this guideline in all Iranian prisons.
Keywords: HIV/AIDS, prison, guideline, indicators, HIV testing, antiretroviral therapy.
Infectious Disorders - Drug Targets
Title:Comparison of HIV Indicators after the Implementation of a New Model for TB and HIV Management in an Iranian Prison
Volume: 20 Issue: 6
Author(s): Behnam Farhoudi, SeyedAhmad SeyedAlinaghi*, Bahar Ataeinia, Mostafa Hosseini, Sirous Jafari, Ramin Alasvand, Mehrzad Tashakoriyan and Minoo Mohraz
Affiliation:
- Iranian Research Center for HIV/AIDS, Tehran University of Medical Sciences, Tehran,Iran
Keywords: HIV/AIDS, prison, guideline, indicators, HIV testing, antiretroviral therapy.
Abstract:
Objectives: A new national clinical guideline for the management of tuberculosis and HIV in Iranian prisons was released in 2011. The aim of this study was to compare HIV indicators in the case and control prisons after implementation of the new guideline.
Methods: This report examines outcomes observed during the pilot phase of its implementation at a case prison from October 2013 to June 2014 compared to a control prison that had not yet implemented the guideline. The case prison included incarcerated individuals in the Great Tehran Prison. A prison in Alborz province was considered as a control group. Pearson’s Chi-squared, two-sample t-test, paired t-test and Kruskal-Wallis were used for the analysis.
Results: The intervention significantly increased the total number of inmates tested for HIV and of diagnoses of HIV-positive inmates in the case prison compared to the control prison (P<0.001). Moreover, coverage of antiretroviral therapy was higher in the case prison compared to the control prison (P=0.015).
Conclusion: We recommend the implementation of this guideline in all Iranian prisons.
Export Options
About this article
Cite this article as:
Farhoudi Behnam, SeyedAlinaghi SeyedAhmad*, Ataeinia Bahar, Hosseini Mostafa, Jafari Sirous, Alasvand Ramin, Tashakoriyan Mehrzad and Mohraz Minoo, Comparison of HIV Indicators after the Implementation of a New Model for TB and HIV Management in an Iranian Prison, Infectious Disorders - Drug Targets 2020; 20 (6) . https://dx.doi.org/10.2174/1871526519666191015151639
DOI https://dx.doi.org/10.2174/1871526519666191015151639 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mechanosensitive Channels: Therapeutic Targets in the Myocardium?
Current Pharmaceutical Design AMP-activated Protein Kinase As a Target For Pathogens: Friends Or Foes?
Current Drug Targets Tofacitinib, an Oral Janus Kinase Inhibitor: Perspectives in Dermatology
Current Medicinal Chemistry Chronic Stress and Diabetes Mellitus: Interwoven Pathologies
Current Diabetes Reviews Isoniazid is Not a Lead Compound for its Pyridyl Ring Derivatives,Isonicotinoyl Amides, Hydrazides, and Hydrazones: A Critical Review
Current Medicinal Chemistry Coumarin Derivatives as Adjuvants: From In Silico Physicochemical Characterization to In Vitro Evaluation against Gram Positive Bacteria
Combinatorial Chemistry & High Throughput Screening In Silico Identification of Human miR 3654 and its Targets Revealed its Involvement in Prostate Cancer Progression
MicroRNA The Lord of the Bacteria: The Fellowship of the Leader and Other Serine Protease Inhibitors
Current Pharmaceutical Design On the Diversity of Oxidative Bioactivation Reactions on Nitrogen- Containing Xenobiotics
Current Drug Metabolism A Pathogenetic Approach to Autoimmune Skin Disease Therapy: Psoriasis and Biological Drugs, Unresolved Issues, and Future Directions
Current Pharmaceutical Design Therapeutic Potential of Natural Products from Terrestrial Plants as TNF-α Antagonist
Current Topics in Medicinal Chemistry Death Due to COVID-19 in an Infant with Combined Immunodeficiencies
Endocrine, Metabolic & Immune Disorders - Drug Targets The Role of Co-Infections in Mother-to-Child Transmission of HIV
Current HIV Research Nonprofit Pharma: Solutions to What Ails the Industry
Current Medicinal Chemistry Privileged Structures in the Design of Potential Drug Candidates for Neglected Diseases
Current Medicinal Chemistry Genetics of the First Seven Proprotein Convertase Enzymes in Health and Disease
Current Genomics Secretory Leukocyte Protease Inhibitor: More than Just A Protease Inhibitor
Current Immunology Reviews (Discontinued) 2-Mercaptobenzothiazole and its Derivatives: Syntheses, Reactions and Applications
Current Organic Chemistry A New Battlefield Towards Global Health in 21<sup>st</sup> Century: Clinical Research Networks
Applied Clinical Research, Clinical Trials and Regulatory Affairs From the Obscure and Mysterious Acute Phase Response to Toll-Like Receptors and the Cytokine Network
Current Immunology Reviews (Discontinued)